<DOC>
	<DOCNO>NCT02486601</DOCNO>
	<brief_summary>This non-randomized pauci-centre , open-label phase II study . The treatment consist chemotherapy FOLFOX nab-paclitaxel follow modality determine Brown University Phase I study . In neoadjuvant setting : 3 month treatment Main criterion Withdraw treatment : case tumor progression , non acceptable toxicity , patient decision . Post-operative treatment ( 6 additional cycle ) recommend , depend result neo-adjuvant treatment ability patient receive adjuvant chemotherapy base tolerance neo-adjuvant treatment general post-operative condition ( i.e . adjuvant treatment progression neo-adjuvant chemotherapy , le 80 % residual viable tumor compare initial tumor volume , acceptable tolerance post-operative PS 0 - 2 ) . Adjuvant treatment must initiate within 8 week post-operatively .</brief_summary>
	<brief_title>NAB-PACLITAXEL Plus FOLFOX Perioperative Chemotherapy Patients With Operable Oesogastric Adenocarcinoma</brief_title>
	<detailed_description>This non-randomized pauci-centre , open-label phase II study . The treatment consist chemotherapy FOLFOX nab-paclitaxel follow modality determine Brown University Phase I study . In neoadjuvant setting : 3 month treatment Main criterion Withdraw treatment : case tumor progression , non acceptable toxicity , patient decision .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Signed date informed consent , willing able comply protocol requirement , Histologically cytologically proven adenocarcinoma low oesophagus stomach , ( 1/3 inferior oesophagus pylorus ) HER2 negative tumor Localized operable disease confirm ( stage IIII ) , No prior therapy localized disease , Age ≥18 year , Performance status ( PS ) 02 , Haematological status : neutrophil ( ANC ) &gt; 2.0x109/L ; platelet &gt; 100x109/L ; haemoglobin ≥9g/dL , Adequate renal function : serum creatinine level &lt; 150µM creatinine clearance test &gt; 30mL/min , Adequate liver function : AST ( SGOT ) ALT ( SGPT ) ≤2.5xULN ( Upper Limit Normal ) Total bilirubin ≤1.5 x ULN , Albumin ≥25g/L Baseline evaluation perform inclusion : clinical blood evaluation 2 week ( 14 day ) prior inclusion , tumor assessment ( CTscan , evaluation nonmeasurable lesion ) 3 week ( 21 day ) prior inclusion , Female patient must surgically sterile , postmenopausal , must commit use reliable appropriate method contraception study least six month end study treatment ( applicable ) . All female patient reproductive potential must negative pregnancy test ( β HCG ) within 72 hour day prior start nabpaclitaxel neoadjuvant adjuvant treatment . Breastfeeding allow . Male patient must agree use effective contraception addition partner use contraceptive method well trial least six month end study treatment , Registration national health care system ( CMU include France ) . Metastatic disease ( stage IV ) Non operable primary tumor Patient use warfarin , Uncontrolled hypercalcemia ( correct serum calcium &gt; 2.55 mmol/l ) , Preexisting permanent neuropathy ( NCI grade ≥2 ) , Known dihydropyrimidine dehydrogenase ( DPD ) deficiency , Concomitant unplanned antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy ) , Treatment investigational medicinal product within 28 day prior study entry , Other serious uncontrolled nonmalignant disease ( eg . active infection require systemic therapy , coronary stenting myocardial infarction stroke past 6 month ) , Known historical active infection HIV , know active infection untreated hepatitis B hepatitis C. Other concomitant previous malignancy , except : i/ adequately treat insitu carcinoma uterine cervix , ii/ basal squamous cell carcinoma skin , iii/ cancer complete remission &gt; 5 year , Patients know allergy excipient study drug , Concomitant administration live , attenuate virus vaccine yellow fever vaccine concomitant administration prophylactic phenytoin Patient medical psychological condition , deem investigator likely interfere patient 's ability sign inform consent cooperate participate study , include tutelage guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>